Table 5. Incremental cost-effectiveness analysis (Functional Limit scenario).
| Total | Incremental | ICER | |||
|---|---|---|---|---|---|
| True cases detected | Cost* | True cases detected | Cost | ||
| No screening | 0 | 0 | — | — | — |
| VIA alone | 257 | 4,383 | 257 | 4,383 | 17 |
| Cytology (Pap-1) plus colpo. | 298 | 38,915 | Dominated*** | Dominated*** | — |
| HPV DNA plus colpo. | 361 | 115,610 | Dominated** | Dominated** | — |
| Cytology (Pap-2) plus colpo. | 373 | 69,865 | 116 | 65,482 | 567 |
ICER = Incremental cost-effectiveness ratio, colpo. = colposcopic biopsy
*For initial screen plus colposcopic biopsy when indicated. Excludes colposcopic biopsy for VIA because not clinically relevant.
**HPV DNA screening was dominated by Pap 2 in that it offered fewer cases for a higher total cost.
***Pap 1 was dominated by Pap 2 in that the marginal cost of identifying cases was higher than with Pap 2.